Amundi Raises Holdings in Repligen Co. (NASDAQ:RGEN)

Amundi grew its position in shares of Repligen Co. (NASDAQ:RGEN) by 11.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 85,863 shares of the biotechnology company’s stock after purchasing an additional 8,790 shares during the quarter. Amundi owned approximately 0.15% of Repligen worth $13,283,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Champlain Investment Partners LLC boosted its stake in shares of Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Repligen during the fourth quarter worth about $52,492,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after buying an additional 203,011 shares during the period. DF Dent & Co. Inc. boosted its stake in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after buying an additional 139,615 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in shares of Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after buying an additional 102,100 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $150.62 on Friday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a 50 day moving average of $157.19 and a 200-day moving average of $148.48. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23. The company has a market cap of $8.44 billion, a price-to-earnings ratio of -295.33, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. As a group, equities analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent analyst reports. Canaccord Genuity Group raised their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Royal Bank of Canada raised their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $181.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.